Clinical Trial

Positive Association of US-FLI With the Severity of CAD

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2024 (before its estimated April 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-02.
Trial Details
NCT Number NCT06541132
Lead Sponsor Chongqing Medical University
Conditions Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease, SYNTAX Score, Ultrasonography
Enrollment 190 participants
Start Date 2022-07-01
Primary Completion 2025-04-28 (estimated)
Study Completion 2025-04-28 (estimated)
Updated on ClinicalTrials.gov 2024-08-21